Abstract
SummaryThe treatment of intra ocular lymphoma with methotrexate is currently used since a decade. The local treatment is effective but often suspensive. The most common dosage is 400 microg/0.1 ml twice a week for 4 weeks then once a week for 4 weeks then once a month. This treatment is not easy to monitor since there is no measurable mass into the eye. One option is to monitor the tumor response with the help of IL10 dosage in the anterior chamber regularly. The IL10 decrease is very well correlated to the decrease of tumoral cells into the eye. The controversy that remains is when to use this local treatment? Is it sufficient if the lymphoma is restricted to the eye? Or should we need to treat systemically the ocular involvement before the occurrence of cerebral tumor? If the patient is treated systemically but relapse only in the eye, the local treatment is a good option. To date there is no evidence based studies demonstrating that ocular lymphoma is better treated systemically or locally and this point remains controversial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
